PRS15 Cost-Benefit Analysis of Bacterial Lysates for Chronic Obstructive Pulmonary Disease in China  by Ma, J. et al.
A778  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  
regression model was used to determine difference of the number of hospitalization 
among groups of severity and health insurance. Costs were converted to $US using 
30.59 Thai-baht per $1US. Results: Among 1,982 patients included, the average age 
was 40.3±24.0 years with 60.7% male. A total of 1,936 patients were non-high risk 
patients, while 46 patients were high-risk patients. There were 1,293 patients under 
universal coverage schemes (UCS), 264 patients under social security schemes, and 
626 patients under civil servant medical benefit schemes (CSMBS). The average 
annual cost/patient was $598±871. In adjusted analyses, the health care cost of high-
risk patients was $67 higher than that of non-high risk patients (95% confidence 
interval (CI); $64–$69). The cost of patients under CSMBS was $109 (95%CI; $105-$113) 
higher than that of patients under UCS. ConClusions: The health care costs in 
a cohort of patients with asthma were substantial and were higher in high-risk 
patients and patients under CSMBS.
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objeCtives: This study aims to propose an appropriate statistical method to ana-
lyse the longitudinal health-related quality of life (HRQoL) data. Methods: This 
was a longitudinal HRQoL study conducted among new smear positive pulmonary 
tuberculosis (PTB) patients diagnosed at the chest clinic of Penang General Hospital 
between March 2010 and February 2011. Eligible patients (i.e., literate and 18 years 
and above) were asked to self-complete the SF-36v2 questionnaire (either in Malay, 
Mandarin, Tamil or English) at the start of the treatment, after the intensive phase 
and at the end of the treatment. The mean physical component summary (PCS) and 
mental component summary (MCS) scores, ranging from 47–53, were considered 
equivalent to the general population norms. Repeated measures ANOVA (with single 
imputations) and linear mixed model were used to analyse the data. Results: A 
total of 216 patients completed the questionnaire at the start of their treatment. 
Out of these, 177 and 153 completed the questionnaire at the second and third 
follow-ups, respectively. Throughout the treatment, the mean PCS and MCS scores 
for the patients were less than 47. In repeated measures ANOVA analysis, level of 
education, diabetes, being alcoholic and cough with sputum were the significant 
predictors of PCS, whereas none of the covariates explained a significant variance 
in the MCS scores. In linear mixed model, ethnicity, marital status, being a smoker, 
productive cough and ≥ 3 TB-related symptoms were the significant predictors of 
PCS. Similarly, covariates such as ethnicity, hypertension, being a smoker, monthly 
income ≥ 1000 MYR and ≥ 3 TB-related symptoms significantly explained variance 
in the MCS scores. ConClusions: The study’s findings indicated compromised 
health among the study participants even at the end of treatment. According to dif-
ferent findings obtained from both methods and the limited assumption in applying 
repeated measures ANOVA, linear mixed model was preferred to analyse this data.
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objeCtives: Stevens - Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) 
are two forms of life-threatening dermatologic condition. The syndromes are very 
severe. They require lots of health care resource. However, there is little informa-
tion about health care resource utilization and cost of managing SJS/TEN. Thus, 
this study aimed to quantify health care use and cost of managing this syndrome 
in Thailand. Methods: A retrospective study using an electronic health database 
from a 1000 bed- university-affiliated hospital in Thailand was undertaken. Patients 
who were admitted with SJS/TEN from 2002 to 2007 were included. The cost was 
determined using the ratio of cost-to-charge of the hospital for each year. The cost 
was converted to 2013 value by consumer price index. The cost was converted to US$ 
using 32.97 Thai-baht per 1 US$. Results: A total of 157 patients were included with 
56.1% of male. Average age of the patients was 45.3±23.0 years. Of those patients, 118 
patients were primarily diagnosed as SJS/TEN, while 39 patients were secondarily 
diagnosed as SJS/TEN. About 146 patients (93.0%) were diagnosed as SJS and the rest 
of them were diagnosed as TEN. The average length of stay (LOS) was 10.1±13.2 days 
for all patients. The LOS for primarily diagnosed patients was 6.8±4.8 days, while 
the LOS for secondarily diagnosed patients was 20.2±22.5 days. Most of patients 
(93.0%) were treated with systemic corticosteroids. Prednisolone was commonly 
used as an oral medication, while dexamethasone was usually used as an inject 
medication. The average cost of managing SJS/TEN for all patients was $1,012±2,563. 
The median cost was $342 (min-max; $11-$26,345). The average cost for primarily 
diagnosed patients was $519±724, while that for secondarily diagnosed patients was 
$2,536±4,713. ConClusions: Health care utilization and cost of managing SJS/TEN 
in Thailand were substantial. Policy makers may consider allocating resources to 
support the development of strategies to minimize preventable SJS/TEN.
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the incidence-based economic burden of asthma within lifetime horizon of around 
16,193 billion VND. ConClusions: Understanding the economic impact of asthma 
on society is fundamental to plan and implement relevant medical policies. The high 
incidence-based economic burden of asthma of around 16,193 billion VND should be 
considered to conduct the health care policies in Vietnam.
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objeCtives: Atopic dermatitis (AD) is a chronic skin disease typically presenting in 
infancy. A literature review was conducted to identify pediatric AD cost estimates in 
Asia-Pacific (AP) countries. Methods: An electronic literature search was conducted 
in PubMed, Google scholar, and Asian electronic reference databases to identify stud-
ies reporting on pediatric AD cost estimates in AP countries. Open text search terms 
were used to maximize the sensitivity of the search strategy. These searches were 
supplemented by manual reviews of bibliographies of the articles reporting cost esti-
mates and discussions with AD experts. Costs were inflated and converted to 2013 
US dollars. Results: Annual AD costs per patient were identified in Australia (cross-
sectional survey of 48 parents of AD children; age 4 months-15 years; total costs for 
all, mild, moderate, and severe cases: $2,745; $925; $3,301; $4,907, respectively; direct 
costs only: $1,400; $636; $1,577; $2,420, respectively), South Korea (cross-sectional 
survey of 196 parents of AD patients; age < 12 years; visiting an allergy clinic; total: 
$3,522; direct: $1,253); Indonesia (model-based; age 0-6; urban; total: $743; direct: 
$740), Malaysia (model-based; age 0-6; urban; total: $576; direct: $398), Philippines 
(model-based; age 0-6; urban; total: $371; direct: $363), Singapore (model-based; age 
0-6; urban; total: $1,097; direct: $957), and Thailand (model and chart review of 3,502 
AD children; age 0-5; direct costs; all, mild, moderate, and severe AD: $199, $124 $415, 
$968, respectively). ConClusions: The economics of pediatric AD in AP has not 
been extensively studied. Based on available evidence, annual pediatric AD costs are 
generally high. Variations in cost estimates are due to between-study differences in 
country of analysis, types of costs included, severity of AD, and costing methodol-
ogy. Further evaluations of the AD costs and the cost-effectiveness of pediatric AD 
prevention strategies in AP countries are warranted.
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objeCtives: Children with a family history of atopic disease receiving cow’s milk 
formula (CMF) are at high risk of atopic dermatitis (AD). Modeling techniques were 
used to estimate the economic impact of AD among urban high-risk children in 
Malaysia, Indonesia, and Singapore. Methods: A cohort Markov model was devel-
oped to simulate the cumulative incidence and costs of AD in 3 cohorts (one per 
country) of urban, high-risk infants partially of completely fed with CMF in early 
infancy (months 0-4). AD incidence was from the GINI study, the largest/longest 
prospective experimental study of infant formula and AD in this population. AD 
treatment patterns and resource use assumptions were dervided from expert opin-
ion (n= 8). Costing of resource use was based on the respective countries’ prices. 
Key modeled outcomes included the overall and annual direct/indirect costs of 
AD (converted to 2013 US$) from diagnosis to age 6. Multivariate probabilistic sen-
sitivity analysis was uses to generate 95% confidence intervals (CI) around study 
outcomes. Results: The 6-year cumulative risk of AD was 38% (95% CI: 22%, 57%). 
The mean overall estimated AD costs/child developing AD was $2,492 (95% CI: $1,887, 
$3,509) in Malaysia, $3,217 (95% CI: $2,339, $4,717) in Indonesia, and $4,753 (95% CI: 
$3,438, $6,961) in Singapore. Expressed on an annual basis, the cost of AD per child 
developing AD was $576 (95% CI: $501, $650) in Malaysia, $743 (95% CI: $605, $876) in 
Indonesia, and $1,097 (95% CI: $900, $1,303) in Singapore. Most of these costs were 
direct costs for physician visits and pharmacologic treatments. ConClusions: By 
age 6, the total cumulative AD-related costs among high-risk urban infants who are 
fed with CMF in early infancy are estimated to range from $2,492 to $4,473. Annual 
AD costs range from $576 to $1,097. Cost-effective AD prevention strategies should 
be considered to reduce this burden.
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objeCtives: Asthma is a major health care problem. Understanding current pat-
terns of health care utilization is important. Several previous studies compared 
health care utilization and cost by severity and health insurance; however, they may 
not be applicable to Thailand. This study aimed to compare health care utilization 
and cost by asthma severity and type of health insurance in Thailand. Methods: 
A retrospective study using an electronic database was conducted in patients with 
asthma who visited a University-affiliated hospital during 2009-2011. The outcomes 
were health care utilization and costs of in-patient and out-patient care. We com-
pared outcomes between groups based on a proxy of severity (high vs. non-high 
risk of emergency department visit) and type of health insurance. Multivariable 
generalized linear regression model with log link function was used to determine 
the difference of average health care cost, while multivariable negative binomial 
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objeCtives: To demonstrate the health economic impact of OM-85, a bacterial 
lysates based immunostimulant, for its approved indications in China. Methods: 
A cost effectiveness decision tree model was constructed. The model compared 
OM-85 with the best supportive care therapy for the treatment of chronic bronchi-
tis and rhinosinusitis in Chinese population. Clinical efficacy and adverse events 
(AE) data were included in the model based on a thorough literature review. All 
localized direct treatment costs, including drug cost, AE costs, and medical treat-
ment costs for underlining diseases were included from Chinese payer perspective 
for both OM-85 and best supportive care group. A Key Opinion Leaders (KOL) survey 
was conducted to validate the local treatment costs. A total of 20 senior physi-
cians specialized in respiratory, ENT, allergy, and immunology fields were selected 
from tertiary hospitals in Beijing, Shanghai, Guangzhou, Hangzhou, Chongqiong, 
Chengdu and Wuhan to form an representative geographic sample. All physicians 
were requested to complete a questionnaire which included the clinical manage-
ment of acute exacerbation of chronic bronchitis and rhinosinusitis in China, the 
management of OM-85 related AEs, and the attitude towards the clinical efficacy 
and effects of OM-85. Incremental cost effectiveness ratio (ICER) was calculated 
based on the above efficacy and cost information. Results: The results indicate 
that, when compared with best supportive care therapy,OM-85 is a dominant 
therapy (with better clinical efficacy and lower overall costs) in Chinese popula-
tion for the clinical management of chronic bronchitis and rhinosinusitis One 
way sensitivity analyses were performed and the ICER result was demonstrated 
to be robust. ConClusions: Based on its clinical efficacy in preventing acute 
exacerbations of chronic bronchitis and rhinosinusitis, OM-85, when compared 
with standard care therapy, proved to be a dominant therapy (better clinical effi-
cacy and lower overall costs) in Chinese population for the clinical management 
of chronic bronchitis and rhinosinusitis.
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objeCtives: Unmotivated smokers are a unique population and have rarely 
been specifically targeted for recruitment into smoking cessation trials. While 
accurate cost data are essential to estimate resource utilization in replicating 
an intervention, currently the costs of recruiting unmotivated smokers are not 
reported in the literature. We aim to describe the costs and recruitment meth-
ods associated with successful enrollment of smokers who are unmotivated to 
quit. Methods: Economic analysis was conducted on data from KC-Quest trial, 
an NIH funded large RCT comparing the efficacy of Motivational Interviewing 
(MI), matched intensity health education (HE), and brief advice (BA) for prompting 
quit attempts and cessation among smokers low in motivation to quit smoking. 
In this study retrospective analysis of cost data was performed to identify direct 
and activity-based time costs incurred for recruitment purposes. Costs were ana-
lyzed from the perspective of a researcher that seeks to replicate this recruitment 
protocol. To determine the most cost effective option to recruit patients for the 
trial one-way sensitivity analysis using a tornado diagram was conducted. All 
costs are reported in 2012 dollar values. Results: A total of 774 persons were 
screened for participation, and 255 were ultimately enrolled in the study. Overall 
cost of recruitment totaled $16,931.94 (direct costs= $12,252.50; activity-based 
time costs= $4,679.43), translating to $21.88 per recruitment contact and $66.40 
per successfully enrolled participant. The most successful recruitment methods 
were newspaper advertisements and word-of-mouth. Financial incentives also 
motivated many to participate. ConClusions: We are the first to report the cost 
of recruiting smokers with low motivation to quit and shed light on this unique 
challenge. Study results may inform decision-makers, researchers, and clinicians 
seeking to enroll for unmotivated smokers. This economic analysis can serve as a 
guide to determine the budget for actively enrolling these patients in future trials 
and suggests the most efficient means to do so.
ReSPiRatoRy-Related diSoRdeRS – Patient-Reported outcomes &  
Patient Preference Studies
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objeCtives: The purpose of this study is to assess health status of Korean adults 
with COPD using EQ5D and the association between health status and disease 
severity using spirometry as a lung function measure. Methods: A stratified 
multistage clustered probability design was used to select a nationally repre-
sentative sample. From the Fourth and Fifth Korea National Health and Nutrition 
Examination Survey, 20,261 adults over the age of 40 years were selected. These 
subjects completed the utility measure, EQ-5D-3L and were separated into four 
severity groups according to FEV1 percent of predicted normal using the GOLD 
clinical guideline. Population sampling weights were applied to adjust for the 
over-sampling of the minority groups. Regression analysis was conducted using 
EQ-5D as the dependent variable to estimate the association between COPD and 
EQ-5D index score with SAS Ver. 9.3 program. Results: Among 20,261 adults, 
2,087 COPD patients were selected based on GOLD criteria (a ratio of FEV1 to 
FVC of less than 0.7). The mean utility of COPD patients was 0.906(SE 0.004) com-
pared to 0.922(SE 0.001) in the non-COPD control group. Utility was significantly 
reduced due to COPD(p= 0.0001). Within each GOLD stage, the variation (SE) was 
objeCtives: Bacterial lysates reduce acute exacerbations for patients with 
chronic obstructive pulmonary disease. The purpose of this study was to conduct 
a cost-benefit analysis of bacterial lysates from a payer perspective through the 
results from a Meta analysis and a Delphi panel survey in China. Methods: A 
cost-benefit analysis was to project the 12-month health benefits and costs asso-
ciated with immunostimulation treatments. Acute exacerbations were served as 
a measure of effectiveness. Treatment effectiveness data were derived from the 
meta-analysis. Costs were obtained from a Delphi panel survey of treating acute 
exacerbation for chronic obstructive pulmonary disease in China. One-way sensi-
tivity analysis was used to explore each parameter’s impacts on the uncertainty 
of the results. Results: The group receiving routine care only was dominated by 
the group with bacterial lysates plus routine care. Sensitivity analysis proved the 
robustness of the results. For a COPD patient, compared to the routine care as 
control group, the alternative treatment with bacterial lysates could reduce 1.9 
exacerbations in 12 months (WMD, -1.865; 95% CI, -2.128 to -1.603; P< 0.00001). The 
projected 12-month cost savings of a patient receiving bacterial lysates plus routine 
care was CNY14476. The cost of patients receiving bacterial lysates plus routine care 
was significantly lower than those receiving routione care only. ConClusions: 
For patients with COPD, treatments with bacterial lysates can improve patient out-
comes and reduce costs.
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objeCtives: To assess, from a societal perspective, the cost-effectiveness of 100% 
whey-based partially hydrolyzed infant formula (pHF-W) compared to standard 
cow’s milk formula (CMF) as an early, short-term nutritional intervention to pre-
vent atopic dermatitis (AD) in high-risk Singaporean infants. Methods: A Markov 
model was developed to simulate, from birth through age 6, the incidence of AD 
and its ensuing burden in cohorts of high-risk infants fed with pHF-W or CMF 
during for the first 4 months of life. Epidemiologic and clinical data were from 
the German Infant Nutritional Intervention (GINI) trial. AD treatment patterns and 
outcomes were based on expert opinion. Key modeled outcomes included reduc-
tion in AD risk, time spent after an AD diagnosis, days with AD symptoms, quality-
adjusted life years (QALYs), and direct/indirect costs (in 2013 Singapore $). A 3% 
annual discount rate was used. Multivariate probabilistic sensitivity analysis was 
used to generate 95% probabilistic confidence intervals (CI) around the modeled 
outcomes. Results: Feeding high-risk infants pHF-W instead of CMF resulted in 
reductions of (i) 14-percentage points (95% CI: 3%, 24%) in the 6-year risk of AD, (ii) 
8.25 months (95% CI: 5.00, 11.61) in the time spent post-AD diagnosis, and (ii) 14.6 
days (95% CI: 8.9, 20.3) with AD symptoms; and in an increase of 0.022 QALYs (95% 
CI: 0.008, 0.074). Estimated AD-related discounted cost (all per child) when feeding 
high-risk infants with pHF-W vs. CMF were $1,316 (95% CI: $858, $2028) and $2,055 
(95% CI: $1,443, $2,820), respectively, for a net difference favoring pHF-W of $739 
(95% CI: $1,138, $326). The mean overall and annualized (undiscounted) cost of AD 
per child developing AD was $5,814 and $1,392, respectively. ConClusions: This 
mathematical model suggests that the burden of AD in childhood is high and that 
feeding high-risk infants with pHF-W instead of CMF should reduce this burden.
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objeCtives: To systematically review the economic evaluations of the Xiyanping 
injection to treat respiratory diseases. Methods: Database as PubMed, ISI Web of 
knowledge, The Cochrane Library, CBM, WanFang Data, CNKI and VIP were electroni-
cally searched from inception to February 28st, 2014. Two reviewers independently 
screened studies according to inclusion and exclusion criteria and extracted data. 
Then, descriptive analysis was performed for included studies. A 10-item quality 
checklist modified was used to appraise the quality of studies. Results: 6 economic 
evaluations and cost studies were included of which 4 studies’ quality were low, 1 
was high and 1 was medium. All studies adequately documented effectiveness of 
interventions. However, the costs of interventions were not well reported in 2 studies. 
2 studies inadequately conducted sensitivity analysis and discounting. The disease of 
6 studies includingbronchitis(2studies), upper respiratory tract infection, herpangina, 
hand-foot-and-mouth disease and viral pneumonia. The studies result showed that 
cost-effectiveness of Xiyanping injection is poor than Tanreqing injection and have 
more adverse reaction in 2 studies and It is poor than Yanhuning injection, but less 
adverse reaction in 2 studies. Xiyanping injection is better than anti-viral medicine 
in 2 studies. 1study indicated that Xiyanping is more cost-effectiveness by atom-
ized than intravenous drip. ConClusions: Xiyanping injection is not better than 
other proprietary Chinese medicine for the treatment of respiratory diseases in cost-
effectiveness analysis, however it is better than anti-viral medicine, and less adverse 
reaction. The quality of included studies is weaken the conclusion. There remains a 
strong need to improve the quality of reporting.
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